A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma

Oncotarget

Volumn 5, Issue 1, 2014, Pages 95-102

  Subbiah, Vivek ^a   Brown, Robert E ^b   McGuire, Mary F ^b   Buryanek, Jamie ^b   Janku, Filip ^a   Younes, Anas ^c   Hong, David ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adolescent and young adult oncology; Biomedical analytics; Brentuximab vedotin; CD30; CD8; Complete response; Exceptional responder; FDG PET; HDAC; Hodgkin's lymphoma; Immune dysregulation; Immunotherapy; Morphoproteomics; mTOR; PI3K AKT mTOR; Rapalog; Sirolimus; T cell regulatory cells; Targeted therapy; Unusual responder; Vorinostat

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CARMUSTINE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; RAPAMYCIN; RITUXIMAB; VINBLASTINE; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; IMMUNOLOGIC FACTOR; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84893823864     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1468     Document Type: Article

References (37)

1. Classics in oncology. Excerpts from: On some morbid appearances of the absorbent glands and spleen, Thomas Hodgkin. CA Cancer J Clin. 1973; 23(1):54-60.
2. Diehl V. Hodgkin's disease--from pathology specimen to cure. N Engl J Med. 2007; 357(19):1968-1971.
3. Klimm B, Schnell R, Diehl V and Engert A. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica. 2005; 90(12):1680-1692.
4. Copeland A and Younes A. Current treatment strategies in Hodgkin lymphomas. Curr Opin Oncol. 2012; 24(5):466-474.
5. Borchmann P, Engert A and Diehl V. Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence! Nat Rev Clin Oncol. 2011; 8(11):636-637.
6. Subbiah V, Ly UK, Khiyami A and O'Brien T. Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report. Journal of medical case reports. 2007; 1:148.
7. Hummel M, Ziemann K, Lammert H, Pileri S, Sabattini E and Stein H. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N Engl J Med. 1995; 333(14):901-906.
8. Halbsguth TV, Boll B, Borchmann P and Diehl V. The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep. 2011; 6(3):164-171.
9. Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med. 2009; 133(4):568-579.
10. Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, Ji Y and Younes A. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 2012; 119(17):4017-4025.
11. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S and Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem. 2011; 286(29):25992-26002.
12. Zhu Z, Jiang W, McGinley JN and Thompson HJ. Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model. Cancer Prev Res (Phila). 2013; 6(4):290-298.
13. Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G and Hancock WW. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol. 2011; 31(5):1022-1029.
14. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O, Brenkman AB, Hijnen DJ, Mutis T, Kalkhoven E, Prakken BJ and Coffer PJ. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood. 2010; 115(5):965-974.
15. Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH, Kerstann KF, Wheeler W, Hemminki K, Linet MS and Goldin LR. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006; 98(18):1321-1330.
16. Asano N, Oshiro A, Matsuo K, Kagami Y, Ishida F, Suzuki R, Kinoshita T, Shimoyama Y, Tamaru J, Yoshino T, Kitamura K, Fukutani H, Morishima Y and Nakamura S. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study. J Clin Oncol. 2006; 24(28):4626-4633.
17. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA and Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008; 93(2):193-200.
18. Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG and Shevach EM. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood. 2009; 113(21):5125-5133.
19. Brown RE and Nazmi RK. The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications. Ann Clin Lab Sci. 2002; 32(4):339-351.
20. Kawamoto K, Pahuja A, Hering BJ and Bansal-Pakala P. Transforming growth factor beta 1 (TGF-beta1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs. Transpl Immunol. 2010; 23(1-2):28-33.
21. Chen CS, Weng SC, Tseng PH and Lin HP. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem. 2005; 280(46):38879-38887.
22. Chen L, Wu J, Pier E, Zhao Y and Shen Z. mTORC2-PKBalpha/Akt1 Serine 473 phosphorylation axis is essential for regulation of FOXP3 Stability by chemokine CCL3 in psoriasis. J Invest Dermatol. 2013; 133(2):418-428.
23. Garber K. Rapamycin may prevent post-transplant lymphoma. J Natl Cancer Inst. 2001; 93(20):1519.
24. Boratynska M and Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transplant international: official journal of the European Society for Organ Transplantation. 2008; 21(6):605-608.
25. Bonatti H, Hoefer D, Rogatsch H, Margreiter R, Larcher C and Antretter H. Successful management of recurrent Epstein-Barr virus-associated multilocular leiomyosarcoma after cardiac transplantation. Transplantation proceedings. 2005; 37(4):1839-1844.
26. Janic MD, Brasanac CD, Jankovic JS, Dokmanovic BL, Krstovski RN and Kraguljac Kurtovic JN. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome. Pediatric blood&cancer. 2009; 53(6):1117-1119.
27. Fasolo A and Sessa C. Targeting mTOR pathways in human malignancies. Current pharmaceutical design. 2012; 18(19):2766-2777.
28. Carew JS, Kelly KR and Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Targeted oncology. 2011; 6(1):17-27.
29. Figlin RA, Kaufmann I and Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer. 2013; 133(4):788-796.
30. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P and Kurzrock R. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PloS one. 2011; 6(4):e18424.
31. Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R and Anderson PM. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). PloS one. 2013; 8(7):e68985.
32. Subbiah V, Trent JC and Kurzrock R. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol. 2010; 28(24):e415.
33. Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? Cancer biology&therapy. 2012; 13(14):1349-1354.
34. Blagosklonny MV. Rapamycin extends life- and health span because it slows aging. Aging. 2013; 5(8):592-598.
35. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP and Blagosklonny MV. Rapamycin extends maximal lifespan in cancer-prone mice. The American journal of pathology. 2010; 176(5):2092-2097.
36. Blagosklonny MV. Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. Aging. 2012; 4(5):350-358.
37. Blagosklonny MV. Progeria, rapamycin and normal aging: recent breakthrough. Aging. 2011; 3(7):685-691.